Navigation Links
Endo Reports First Quarter Financial Results
Date:5/7/2013

have focused on assessing our current strategy and operations with a view to identifying our best opportunities for growth and improving profitability.  I look forward to sharing these plans in the months ahead."FINANCIAL PERFORMANCE AT A GLANCE($ in thousands, except per share amounts)1st Quarter20132012ChangeTotal Revenues$

708,519$

690,6333%Reported Net Income$

15,349$

(87,345)NMReported Diluted EPS$

0.14$

(0.75)NMAdjusted Net Income$

123,238$

106,30016%Adjusted Diluted EPS$

1.09$

0.8725% 

ENDO PHARMACEUTICALSFirst quarter 2013 branded pharmaceutical revenues were $358 million, a 2 percent decrease compared to first quarter 2012 branded pharmaceutical revenues.  This decline was primarily attributable to the decrease in net sales of LIDODERM. First quarter 2013 net sales of LIDODERM decreased 11 percent compared to first quarter 2012. This decrease is primarily attributable to the company's previously announced Supply Agreement with Actavis. As part of that agreement, Endo is providing, at no cost, $12 million per month of branded LIDODERM (valued at equivalent wholesale acquisition cost) to the wholesale affiliate of Actavis for its distribution.

First quarter 2013 net sales of OPANA ER decreased 31 percent compared to first quarter 2012. This decrease is primarily attributable to a supply disruption at the end of first quarter 2012 that led some patients to switch to other pain relief products.  In addition, the brand is now subject to the headwinds of a non-AB rated generic that launched in January 2013.

In Aug. 2012, Endo filed a Citizen Petition requesting, in part, that FDA determine that the discontinued formulation of OPANA ER was withdrawn from the market for reasons of safety. In Nov. 2012, the company supplemented this Citizen Petition to include emerging safety data that the company believes  suggests that the first
'/>"/>

SOURCE Endo Health Solutions
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
(Date:12/24/2014)... Wis. , Dec. 23, 2014 PuraMed ... marketer of over-the-counter (OTC) medicinal and healthcare products, announced ... of MigraPure® H, a hemp-based, advanced headache relief product, ... dispensaries in Colorado , ... . With the MigraPure H Advanced headache ...
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
(Date:12/26/2014)... (PRWEB) December 26, 2014 The Biofeedback ... place March 24-28, 2015 in Rome, Italy and is ... includes workshops on a wide variety of ... well as peak performance training in athletes. The scientific ... the world. , Biofeedback monitoring allows clients to see ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... 2014 When head lice hits a home ... frenzy to get rid of it while keeping it from ... Gables now have the solution right in their neighborhood: ... Lice Troopers provides full spectrum head lice screening and treatment ... including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Cipla has offered to manufacture an antiviral drug for ... by Glaxo Smithkline. It has already made Tamiflu in its ... well known and popular as Tamiflu has but is cheaper ... Hameid, CEO of Cipla in a press release said:‘‘Zanamivir is ...
... as the first most common cause for death in ... stress echocardiography that can help predict life-threatening heart problems ... conducted among a group of diabetic women aged between ... type of stress test for suspected coronary disease that ...
... form chronic back pain, an increasing attention is being ... study has established that chiropractic care produces significantly // ... underwent the therapy had higher pain relief and satisfaction ... medical care. , ,The study has been conducted ...
... detected by using a hand-held scope called VELscope, which has ... by National Institute of Dental Craniofacial Research. The devise emits ... white light in detection of cancerous lesions in the mouth. ... oral cancer as better treatment is achieved when oral cancer ...
... National Laboratory are studying the biopolymer structural dynamics of ... new theory on protein folding unfolds the mystery of ... to diseases and the study is to be published ... Sciences. , ,The researchers used a technique called ...
... Britain can look forward to some relief, as a cannabis-based ... time, following approval from the Home Office for its importation ... be able to obtain an unlicensed, cannabis-based medicine on prescription ... it is yet to be licensed in the UK. The ...
Cached Medicine News:Health News:Cipla In India Can Manufacture Drug For Bird Flu 2Health News:Cipla In India Can Manufacture Drug For Bird Flu 3Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2Health News:Back Pain Can Now Be Cost-Effectively Treated By Chiropractic Care 2Health News:Relief For British MS Patients: Cannabis-Based Oral Spray 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
Red Latex Bardex I.C. Foley 2-Way Catheter (Council Model)...
The BARDEX I.C. Catheter represents Bard's newest technology in providing protection against NUTI....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: